Monitoring Glycemia in Diabetes

被引：7
作者：
Healy, Sara J. [1 ]
Dungan, Kathleen M. [1 ]
机构：
[1] Ohio State Univ, Wexner Med Ctr, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA
来源：
MEDICAL CLINICS OF NORTH AMERICA | 2015年 / 99卷 / 01期
关键词：
Glucose monitor; Self-monitored blood glucose; Continuous glucose monitoring; HbA1c; AUGMENTED PUMP THERAPY; BLOOD-GLUCOSE; HEMOGLOBIN A(1C); GLYCATED ALBUMIN; A1C REDUCTION; SENSOR; ACCURACY; MANAGEMENT; INJECTION; COMPLICATIONS;
D O I：
10.1016/j.mcna.2014.08.017
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Monitoring of glycemic control is a key component of the diabetes treatment plan. Patients who are not meeting targets often require more intensive monitoring, ranging from frequent self-monitored glucose to continuous glucose monitoring in order to facilitate medication and lifestyle changes. However, more intensive monitoring demands more training and a structured plan for interpretation and use of the data. Better patient and provider tools to support decision-making and progress toward an artificial pancreas may help to alleviate this burden.
引用
收藏
页码：35 / +
页数：12
相关论文
共 56 条
  • [1] Standards of Medical Care in Diabetes-2014
    不详
    [J]. DIABETES CARE, 2014, 37 : S14 - S80
  • [2] [Anonymous], 2009, INT DIAB FED CLIN PR
  • [3] Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes
    Battelino, Tadej
    Phillip, Moshe
    Bratina, Natasa
    Nimri, Revital
    Oskarsson, Per
    Bolinder, Jan
    [J]. DIABETES CARE, 2011, 34 (04) : 795 - 800
  • [4] Factors Predictive of Use and of Benefit From Continuous Glucose Monitoring in Type 1 Diabetes
    Beck, Roy W.
    Buckingham, Bruce
    Miller, Kellee
    Wolpert, Howard
    Xing, Dongyuan
    Block, Jennifer M.
    Chase, H. Peter
    Hirsch, Irl
    Kollman, Craig
    Laffel, Lori
    Lawrence, Jean M.
    Milaszewski, Kerry
    Ruedy, Katrina J.
    Tamborlane, William V.
    [J]. DIABETES CARE, 2009, 32 (11) : 1947 - 1953
  • [5] Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
    Bergenstal, Richard M.
    Klonoff, David C.
    Garg, Satish K.
    Bode, Bruce W.
    Meredith, Melissa
    Slover, Robert H.
    Ahmann, Andrew J.
    Welsh, John B.
    Lee, Scott W.
    Kaufman, Francine R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (03) : 224 - 232
  • [6] Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
    Bergenstal, Richard M.
    Tamborlane, William V.
    Ahmann, Andrew
    Buse, John B.
    Dailey, George
    Davis, Stephen N.
    Joyce, Carol
    Peoples, Tim
    Perkins, Bruce A.
    Welsh, John B.
    Willi, Steven M.
    Wood, Michael A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (04) : 311 - 320
  • [7] STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS CONSENSUS PANEL ON CONTINUOUS GLUCOSE MONITORING
    Blevins, Thomas C.
    Bode, Bruce W.
    Garg, Satish K.
    Grunberger, George
    Hirsch, Irl B.
    Jovanovic, Lois
    Nardacci, Elizabeth
    Orzeck, Eric A.
    Roberts, Victor L.
    Tamborlane, William V.
    [J]. ENDOCRINE PRACTICE, 2010, 16 (05) : 730 - 745
  • [8] Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator)
    Buckingham, Bruce
    Xing, Dongyuan
    Weinzimer, Stu
    Fiallo-Scharer, Rosanna
    Kollman, Craig
    Mauras, Nelly
    Tsalikian, Eva
    Tamborlane, William
    Wysocki, Tim
    Ruedy, Katrina
    Beck, Roy
    [J]. PEDIATRIC DIABETES, 2008, 9 (02) : 142 - 147
  • [9] Baseline Predictors of A1C Reduction in Adults Using Sensor-Augmented Pump Therapy or Multiple Daily Injection Therapy: The STAR 3 Experience
    Buse, John B.
    Dailey, George
    Ahmann, Andrew A.
    Bergenstal, Richard M.
    Green, Jennifer B.
    Peoples, Tim
    Tanenberg, Robert J.
    Yang, Qingqing
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2011, 13 (06) : 601 - 606
  • [10] The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients A 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study)
    Charpentier, Guillaume
    Benhamou, Pierre-Yves
    Dardari, Dured
    Clergeot, Annie
    Franc, Sylvia
    Schaepelynck-Belicar, Pauline
    Catargi, Bogdan
    Melki, Vincent
    Chaillous, Lucy
    Farret, Anne
    Bosson, Jean-Luc
    Penfornis, Alfred
    [J]. DIABETES CARE, 2011, 34 (03) : 533 - 539
123456